Context Therapeutics Inc.
CNTXHealthcare|Biotechnology|US
$0.19
+0.01 (+2.98%)
DCF Value
$0.67
Tangible Book / Share
$0.40
Cash / Share
$0.45
Financials
Financial Snapshot
Market Cap
$17.8M
Enterprise Value
-$25.0M
Revenue (TTM)
$0.00
Net Income (TTM)
-$46.0M
Cash & Investments
$43.0M
Net Cash
$42.7M
Free Cash Flow (TTM)
-$34.0M
Operating CF (TTM)
-$34.0M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$43.0M
Quarterly Burn
$8.5M
Monthly Burn
$2.8M
Est. Runway
~5.1 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $226.6K | $341.0K | $49.6M | $35.5M | $14.4M | $94.4M | $66.0M | $43.0M | |
| Operating Cash Flow | -$2.8M | -$1.0M | -$8.8M | -$13.5M | -$21.0M | -$14.6M | -$26.4M | -$34.0M | |
| Free Cash Flow | -$2.8M | -$1.0M | -$9.0M | -$14.1M | -$21.0M | -$29.3M | -$26.4M | -$34.0M | |
| Capital Expenditure | $0.00 | $0.00 | -$250.0K | -$536.8K | $0.00 | -$14.8M | -$33.9K | -$55.7K | |
| Financing Cash Flow | $2.0M | $1.1M | $58.4M | -$102.1K | $0.00 | $109.3M | -$15.3K | $0.00 |
R&D Spending
R&D (TTM)
$40.1M
R&D Intensity
—
R&D Growth vs Prior
+25.9%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $2.4M | $1.6M | $3.8M | $7.1M | $17.8M | $22.7M | $31.9M | $40.1M | |
| SG&A | $3.0M | $930.7K | $3.6M | $7.8M | $7.3M | $7.2M | $7.8M | $8.6M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.1K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$4.1K | |
| R&D | $2.4M | $1.6M | $3.8M | $7.1M | $17.8M | $22.7M | $31.9M | $40.1M | |
| SG&A | $3.0M | $930.7K | $3.6M | $7.8M | $7.3M | $7.2M | $7.8M | $8.6M | |
| Operating Income | -$5.4M | -$2.6M | -$10.5M | -$15.4M | -$25.1M | -$29.9M | -$39.7M | -$48.7M | |
| Interest Expense | $1.1M | $661.2K | $64.2K | $547.3K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$6.4M | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M | -$46.0M | |
| Net Income | -$6.4M | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M | -$46.0M | |
| EPS (Diluted) | -0.68 | 0.10 | -3.69 | -0.93 | -1.50 | -0.46 | -0.38 | -0.48 | |
| EBITDA | -$5.4M | -$2.6M | -$10.5M | -$14.9M | -$24.0M | -$26.7M | -$36.1M | -$45.9M | |
| Shares Out. (M) | 10.96 | 10.96 | 2.83 | 15.97 | 15.97 | 58.42 | 95.19 | 95.18 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $226.6K | $341.0K | $49.6M | $35.5M | $14.4M | $94.4M | $66.0M | $43.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $239.6K | $349.7K | $51.3M | $37.9M | $16.0M | $97.9M | $68.4M | $45.8M | |
| Total Assets | $273.5K | $467.3K | $51.3M | $38.0M | $16.1M | $98.1M | $68.5M | $46.1M | |
| Total Current Liabilities | $24.1M | $9.5M | $3.0M | $3.2M | $4.2M | $2.7M | $8.0M | $7.9M | |
| Long-Term Debt | $0.00 | $69.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $77.5K | |
| Total Liabilities | $24.2M | $17.4M | $3.0M | $3.2M | $4.2M | $2.9M | $8.0M | $8.0M | |
| Stockholders' Equity | -$24.0M | -$16.9M | $48.3M | $34.8M | $11.9M | $95.3M | $60.5M | $38.2M | |
| Retained Earnings | -$25.4M | -$18.8M | -$29.3M | -$44.1M | -$68.1M | -$94.8M | -$130.9M | -$154.1M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8M | -$1.0M | -$8.8M | -$13.5M | -$21.0M | -$14.6M | -$26.4M | -$34.0M | |
| Capital Expenditure | $0.00 | $0.00 | -$250.0K | -$536.8K | $0.00 | -$14.8M | -$33.9K | -$55.7K | |
| Free Cash Flow | -$2.8M | -$1.0M | -$9.0M | -$14.1M | -$21.0M | -$29.3M | -$26.4M | -$34.0M | |
| Investing Cash Flow | $0.00 | $0.00 | -$250.0K | -$536.8K | $0.00 | -$14.8M | -$2.0M | -$6.6M | |
| Financing Cash Flow | $2.0M | $1.1M | $58.4M | -$102.1K | $0.00 | $109.3M | -$15.3K | $0.00 | |
| Issuance of Stock | $0.00 | $0.00 | $53.4M | -$102.1K | $0.00 | $109.3M | -$15.3K | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $2.0M | $149.1K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $775.3K | $219.2K | $511.1K | $976.4K | $1.1M | $841.9K | $1.3M | $1.6M | |
| Net Change in Cash | -$878.7K | $114.4K | $49.3M | -$14.1M | -$21.0M | $80.0M | -$28.4M | -$40.5M |
Dilution Tracker
Shares outstanding grew 768.5% over 5 years — significant dilution
Shares Outstanding
92M
5-Year Share Growth
+768.5%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 10.96 | 10.96 | 2.83 | 15.97 | 15.97 | 58.42 | 95.19 | 95.18 | |
| Change vs Prior % | — | -0.0% | -74.1% | 463.4% | 0.0% | 265.9% | 62.9% | -0.0% | |
| Stock Issuance | $0.00 | $0.00 | $53.4M | -$102.1K | $0.00 | $109.3M | -$15.3K | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $775.3K | $219.2K | $511.1K | $976.4K | $1.1M | $841.9K | $1.3M | $1.6M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | 26.6% | -39.3% | -21.7% | -42.7% | -201.9% | -28.1% | -59.7% | -82.1% | |
| ROA % | -2333.8% | 1421.7% | -20.4% | -39.1% | -149.2% | -27.2% | -52.7% | -99.6% | |
| ROIC % | 270.0% | 80.5% | -21.8% | -44.2% | -211.2% | -31.3% | -65.5% | -126.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 52.2% | -309.2% | -46.1% | -63.0% | -19.3% | -32.7% | |
| Net Income | 0.0% | 204.1% | -257.4% | -41.9% | -61.5% | -11.5% | -35.2% | |
| EPS (Diluted) | 0.0% | 114.7% | -3790.0% | 74.8% | -61.3% | 69.3% | 17.4% | |
| Operating Cash Flow | 0.0% | 63.5% | -750.5% | -54.0% | -55.3% | 30.8% | -81.3% | |
| Free Cash Flow | 0.0% | 63.5% | -774.7% | -55.7% | -49.4% | -39.3% | 9.9% | |
| R&D Expense | 0.0% | -31.9% | 131.7% | 86.4% | 150.8% | 27.7% | 40.3% | |
| SG&A Expense | 0.0% | -68.6% | 290.4% | 114.4% | -6.4% | -0.9% | 8.6% | |
| Total Assets | 0.0% | 70.8% | 10878.2% | -26.0% | -57.7% | 510.9% | -30.2% | |
| Book Value / Share | 0.0% | 29.4% | 1203.2% | -87.2% | -65.8% | 119.3% | -61.0% | |
| Debt | 0.0% | -72.7% | -100.0% | 0.0% | -100.0% | 0.0% | -48.9% | |
| Diluted Shares | 0.0% | -0.0% | -74.1% | 463.4% | 0.0% | 265.9% | 62.9% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.48
10Y Low / Med / High0.16 / 0.64 / 2.31
EV/EBITDA0.54
10Y Low / Med / High1.23 / 1.68 / 4.00
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.67
Tangible Book / Share
$0.40
Net Current Assets / Share
$0.41
Graham Net-Net
$0.37
Cash / Share
$0.45
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -7.50 | 51.00 | -0.72 | -0.70 | -0.75 | -2.28 | -3.87 | -0.40 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -2.33 | -3.30 | 0.16 | 0.30 | 1.52 | 0.64 | 2.31 | 0.48 | |
| EV/EBITDA | -14.42 | -23.91 | 4.00 | 1.68 | -0.15 | 1.23 | -2.05 | 0.54 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-5.64
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $2.0M | $0.00 | $2.5M |
| Net Income | -$45.2M | -$40.8M | -$59.3M |
| EPS | $-0.46 | $-0.43 | $-0.55 |
| # Analysts (EPS) | 7 | 6 | 6 |